Skip to Main Content
DownloadHi-Res Photo

Noffar Bar, MD

Assistant Professor

Contact Information

Noffar Bar, MD

Mailing Address

  • Hematology

    PO Box 208028

    New Haven, CT, 06520-8028

    United States

Related Links

Yale Medicine

Patient Care

Are you a patient?Please visit the Yale Medicine website for information about the services we offer and making an appointment.View Doctor Profile

Research Summary

Dr. Bar is a member of the American Society of Clinical Oncology as well as the American Society of Hematology. She was awarded the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma.

Extensive Research Description

Dr. Bar is a member of the American Society of Clinical Oncology as well as the American Society of Hematology. She was awarded grant support through the Conquer Cancer Foundation’s Young Investigator Award for her work looking at the prevention of multiple myeloma. Dr. Bar's research interests focus on improving the care of patients with multiple myeloma and other plasma cell dyscrasias.

Coauthors

Selected Publications

Clinical Trials

ConditionsStudy Title
Multiple MyelomaA Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA, Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Subjects With Relapsed and Lenalidomide-Refractory Multiple Myeloma
Hodgkin's LymphomaA Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies
Multiple MyelomaPhase II Trial of Daratumumab Retreatment in Patients With Relapsed Multiple Myeloma
KidneyA Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation
Multiple MyelomaA Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.
Multiple MyelomaA Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
Multiple MyelomaMLN9708 (Ixazomib) and MLN4924 (Pevonedistat) in Relapsed/Refractory Multiple Myeloma Patients: A Phase 1b Trial
BreastA Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
Multiple MyelomaDaratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)
Hodgkin's Lymphoma; Lymphoid Leukemia; Non-Hodgkin's LymphomaManaged Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release
Multiple MyelomaPhase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination With Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Multiple MyelomaGlobal Response Assessment by Advanced Imaging and Myeloma Lesion Biopsies During Induction Therapy of Multiple Myeloma with Carfilzomib Lenalidomide Dexamethasone (CRD)
Edit Profile